| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 65 | 2022 | 196 | 4.410 |
Why?
|
| Prostatectomy | 48 | 2017 | 68 | 2.160 |
Why?
|
| Prostate-Specific Antigen | 29 | 2019 | 64 | 1.400 |
Why?
|
| Male | 129 | 2023 | 9556 | 1.250 |
Why?
|
| Humans | 162 | 2023 | 16832 | 1.250 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2019 | 222 | 1.080 |
Why?
|
| Middle Aged | 106 | 2022 | 7515 | 1.020 |
Why?
|
| Incidence | 18 | 2021 | 1229 | 0.930 |
Why?
|
| Adenoma | 2 | 2022 | 97 | 0.910 |
Why?
|
| Aged | 89 | 2022 | 5901 | 0.910 |
Why?
|
| Adult | 74 | 2023 | 7255 | 0.800 |
Why?
|
| Papillomavirus Vaccines | 9 | 2017 | 113 | 0.750 |
Why?
|
| California | 35 | 2021 | 2244 | 0.750 |
Why?
|
| Female | 70 | 2023 | 12193 | 0.710 |
Why?
|
| Autoimmune Diseases | 3 | 2017 | 19 | 0.700 |
Why?
|
| Aged, 80 and over | 41 | 2021 | 1887 | 0.690 |
Why?
|
| Depressive Disorder | 2 | 2022 | 177 | 0.670 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 162 | 0.670 |
Why?
|
| Continental Population Groups | 3 | 2020 | 255 | 0.660 |
Why?
|
| Retrospective Studies | 43 | 2022 | 2463 | 0.660 |
Why?
|
| Mastectomy | 6 | 2014 | 34 | 0.630 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 57 | 0.600 |
Why?
|
| Health Status Disparities | 1 | 2020 | 145 | 0.580 |
Why?
|
| Papillomavirus Infections | 7 | 2017 | 141 | 0.570 |
Why?
|
| Follow-Up Studies | 34 | 2019 | 1058 | 0.560 |
Why?
|
| Risk Factors | 24 | 2022 | 3108 | 0.540 |
Why?
|
| Macular Degeneration | 1 | 2018 | 14 | 0.540 |
Why?
|
| Data Accuracy | 1 | 2017 | 26 | 0.520 |
Why?
|
| Prostate | 8 | 2022 | 23 | 0.490 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 635 | 0.470 |
Why?
|
| Hematuria | 4 | 2020 | 7 | 0.470 |
Why?
|
| Obesity | 7 | 2012 | 811 | 0.470 |
Why?
|
| Research Design | 1 | 2017 | 319 | 0.460 |
Why?
|
| Adolescent | 31 | 2022 | 3464 | 0.450 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2015 | 5 | 0.450 |
Why?
|
| Hysterectomy | 1 | 2015 | 19 | 0.450 |
Why?
|
| Clinical Protocols | 1 | 2015 | 38 | 0.450 |
Why?
|
| Hospitalization | 6 | 2022 | 816 | 0.450 |
Why?
|
| Neoplasm Staging | 24 | 2015 | 322 | 0.450 |
Why?
|
| Smoking | 6 | 2017 | 373 | 0.430 |
Why?
|
| Biomarkers, Tumor | 10 | 2014 | 130 | 0.430 |
Why?
|
| Breast Neoplasms | 8 | 2014 | 913 | 0.430 |
Why?
|
| Cohort Studies | 28 | 2023 | 2396 | 0.430 |
Why?
|
| Child | 24 | 2022 | 2433 | 0.420 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2020 | 53 | 0.410 |
Why?
|
| Insulin | 2 | 2006 | 181 | 0.410 |
Why?
|
| Adenocarcinoma | 10 | 2013 | 160 | 0.400 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 5 | 2017 | 31 | 0.400 |
Why?
|
| Meningococcal Vaccines | 3 | 2019 | 40 | 0.390 |
Why?
|
| Time Factors | 19 | 2021 | 989 | 0.390 |
Why?
|
| Electronic Health Records | 6 | 2021 | 702 | 0.380 |
Why?
|
| Vaccination | 5 | 2021 | 725 | 0.370 |
Why?
|
| Glomerular Filtration Rate | 5 | 2019 | 157 | 0.360 |
Why?
|
| Postoperative Complications | 7 | 2015 | 103 | 0.350 |
Why?
|
| Erectile Dysfunction | 4 | 2017 | 18 | 0.350 |
Why?
|
| Receptors, Androgen | 3 | 2008 | 9 | 0.340 |
Why?
|
| Survival Rate | 20 | 2017 | 247 | 0.340 |
Why?
|
| Hepatitis B Vaccines | 2 | 2022 | 44 | 0.330 |
Why?
|
| Risk Assessment | 7 | 2020 | 1047 | 0.330 |
Why?
|
| Hepatitis B | 2 | 2022 | 43 | 0.330 |
Why?
|
| Salvage Therapy | 8 | 2019 | 13 | 0.330 |
Why?
|
| Proportional Hazards Models | 11 | 2018 | 657 | 0.320 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2020 | 40 | 0.310 |
Why?
|
| Urologic Neoplasms | 3 | 2016 | 7 | 0.300 |
Why?
|
| Vaccines | 2 | 2022 | 225 | 0.290 |
Why?
|
| Disease Progression | 21 | 2019 | 252 | 0.290 |
Why?
|
| Prospective Studies | 10 | 2022 | 1186 | 0.290 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 43 | 0.280 |
Why?
|
| Creatinine | 7 | 2015 | 67 | 0.280 |
Why?
|
| Pituitary Gland | 1 | 2008 | 1 | 0.270 |
Why?
|
| Pituitary Neoplasms | 1 | 2008 | 2 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2020 | 677 | 0.270 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 20 | 0.270 |
Why?
|
| Product Surveillance, Postmarketing | 4 | 2017 | 99 | 0.260 |
Why?
|
| Brachytherapy | 3 | 2017 | 5 | 0.260 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 393 | 0.260 |
Why?
|
| Recovery of Function | 2 | 2017 | 25 | 0.260 |
Why?
|
| C-Reactive Protein | 2 | 2006 | 52 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2017 | 353 | 0.250 |
Why?
|
| Young Adult | 11 | 2020 | 2456 | 0.250 |
Why?
|
| Blood Glucose | 3 | 2013 | 315 | 0.250 |
Why?
|
| Prognosis | 21 | 2014 | 568 | 0.240 |
Why?
|
| United States | 8 | 2023 | 3858 | 0.240 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 346 | 0.230 |
Why?
|
| Age Factors | 13 | 2020 | 814 | 0.230 |
Why?
|
| Managed Care Programs | 3 | 2013 | 275 | 0.220 |
Why?
|
| Insulin Resistance | 1 | 2006 | 127 | 0.220 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 215 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 189 | 0.220 |
Why?
|
| Body Weight | 1 | 2006 | 197 | 0.220 |
Why?
|
| Urology | 3 | 2020 | 4 | 0.220 |
Why?
|
| European Continental Ancestry Group | 4 | 2020 | 400 | 0.220 |
Why?
|
| Disease-Free Survival | 16 | 2019 | 54 | 0.220 |
Why?
|
| Treatment Outcome | 16 | 2017 | 1098 | 0.210 |
Why?
|
| Weight Loss | 2 | 2006 | 302 | 0.210 |
Why?
|
| Marijuana Smoking | 2 | 2015 | 40 | 0.210 |
Why?
|
| Pneumococcal Vaccines | 3 | 2022 | 67 | 0.210 |
Why?
|
| Cause of Death | 3 | 2020 | 171 | 0.210 |
Why?
|
| Preventive Health Services | 3 | 2017 | 142 | 0.210 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 553 | 0.210 |
Why?
|
| Quality of Life | 2 | 2017 | 477 | 0.200 |
Why?
|
| Body Mass Index | 6 | 2015 | 925 | 0.200 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 33 | 0.200 |
Why?
|
| Algorithms | 3 | 2017 | 210 | 0.190 |
Why?
|
| Glucose Intolerance | 1 | 2003 | 45 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 653 | 0.190 |
Why?
|
| Prevalence | 6 | 2018 | 785 | 0.190 |
Why?
|
| Multivariate Analysis | 12 | 2016 | 489 | 0.180 |
Why?
|
| Health Maintenance Organizations | 3 | 2012 | 358 | 0.180 |
Why?
|
| Mass Screening | 2 | 2022 | 670 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2020 | 116 | 0.170 |
Why?
|
| Predictive Value of Tests | 13 | 2013 | 325 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2015 | 107 | 0.170 |
Why?
|
| Surveys and Questionnaires | 6 | 2018 | 1204 | 0.170 |
Why?
|
| RNA, Messenger | 1 | 2021 | 66 | 0.170 |
Why?
|
| Masks | 1 | 2021 | 4 | 0.170 |
Why?
|
| Morbidity | 2 | 2020 | 56 | 0.170 |
Why?
|
| Carcinoma | 4 | 2004 | 19 | 0.170 |
Why?
|
| Occupational Diseases | 1 | 2021 | 33 | 0.170 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 140 | 0.170 |
Why?
|
| Hispanic Americans | 2 | 2020 | 350 | 0.170 |
Why?
|
| Hip Fractures | 1 | 2022 | 72 | 0.170 |
Why?
|
| African Americans | 3 | 2020 | 394 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2021 | 57 | 0.170 |
Why?
|
| Air Pollution | 1 | 2021 | 46 | 0.170 |
Why?
|
| Robotic Surgical Procedures | 2 | 2017 | 8 | 0.160 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 12 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 1 | 2022 | 126 | 0.160 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 30 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 104 | 0.160 |
Why?
|
| Mothers | 2 | 2013 | 104 | 0.160 |
Why?
|
| Case-Control Studies | 7 | 2022 | 995 | 0.160 |
Why?
|
| Coinfection | 1 | 2020 | 28 | 0.160 |
Why?
|
| Colonoscopy | 1 | 2022 | 261 | 0.160 |
Why?
|
| Kidney Diseases | 3 | 2006 | 51 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2007 | 12 | 0.150 |
Why?
|
| Cystoscopy | 3 | 2009 | 4 | 0.150 |
Why?
|
| Health Personnel | 1 | 2021 | 132 | 0.150 |
Why?
|
| Meningococcal Infections | 1 | 2019 | 17 | 0.150 |
Why?
|
| Lymph Node Excision | 7 | 2005 | 13 | 0.150 |
Why?
|
| Sex Characteristics | 2 | 2006 | 58 | 0.150 |
Why?
|
| Cryosurgery | 1 | 2019 | 1 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 192 | 0.140 |
Why?
|
| Watchful Waiting | 2 | 2017 | 19 | 0.140 |
Why?
|
| Ambulatory Care | 2 | 2022 | 205 | 0.140 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 247 | 0.140 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 4 | 2004 | 4 | 0.140 |
Why?
|
| Computer Simulation | 2 | 2009 | 84 | 0.130 |
Why?
|
| Sweat Glands | 1 | 1997 | 1 | 0.130 |
Why?
|
| Tilt-Table Test | 1 | 1997 | 1 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 1997 | 3 | 0.130 |
Why?
|
| Vagus Nerve | 1 | 1997 | 2 | 0.130 |
Why?
|
| Urination | 1 | 2017 | 1 | 0.130 |
Why?
|
| Cell Nucleus | 2 | 2008 | 2 | 0.130 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2017 | 15 | 0.130 |
Why?
|
| Diabetes, Gestational | 1 | 2021 | 330 | 0.130 |
Why?
|
| Length of Stay | 2 | 2015 | 169 | 0.130 |
Why?
|
| Abortion, Spontaneous | 1 | 2017 | 49 | 0.130 |
Why?
|
| Kidney Transplantation | 3 | 2007 | 28 | 0.130 |
Why?
|
| Meningitis, Meningococcal | 1 | 2017 | 6 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2020 | 292 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 28 | 0.120 |
Why?
|
| Chromosome Aberrations | 3 | 2007 | 6 | 0.120 |
Why?
|
| Papillomaviridae | 1 | 2017 | 58 | 0.120 |
Why?
|
| Sexual Behavior | 1 | 2017 | 112 | 0.120 |
Why?
|
| Aging | 1 | 1997 | 146 | 0.120 |
Why?
|
| ROC Curve | 5 | 2013 | 68 | 0.120 |
Why?
|
| Robotics | 2 | 2017 | 5 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 374 | 0.120 |
Why?
|
| Blood Pressure | 1 | 1997 | 278 | 0.120 |
Why?
|
| Risk | 6 | 2020 | 453 | 0.110 |
Why?
|
| Operative Time | 1 | 2015 | 4 | 0.110 |
Why?
|
| Logistic Models | 6 | 2016 | 796 | 0.110 |
Why?
|
| Organ Size | 1 | 2015 | 16 | 0.110 |
Why?
|
| Delivery, Obstetric | 1 | 2015 | 16 | 0.110 |
Why?
|
| Reference Values | 3 | 2008 | 78 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2017 | 140 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2013 | 53 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 30 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2008 | 41 | 0.110 |
Why?
|
| Lymph Nodes | 5 | 2005 | 16 | 0.110 |
Why?
|
| Surgeons | 1 | 2015 | 13 | 0.110 |
Why?
|
| Survival Analysis | 9 | 2008 | 191 | 0.110 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2005 | 3 | 0.110 |
Why?
|
| Correspondence as Topic | 1 | 2014 | 4 | 0.110 |
Why?
|
| Registries | 4 | 2017 | 449 | 0.110 |
Why?
|
| Health Communication | 1 | 2014 | 16 | 0.110 |
Why?
|
| Testicular Neoplasms | 1 | 2014 | 8 | 0.110 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2014 | 8 | 0.110 |
Why?
|
| Mortality | 2 | 2020 | 116 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 94 | 0.100 |
Why?
|
| Odds Ratio | 6 | 2016 | 569 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2008 | 268 | 0.100 |
Why?
|
| Sensitivity and Specificity | 7 | 2013 | 291 | 0.100 |
Why?
|
| BRCA2 Protein | 2 | 2004 | 5 | 0.100 |
Why?
|
| BRCA1 Protein | 2 | 2004 | 7 | 0.100 |
Why?
|
| Animals | 4 | 2008 | 237 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2013 | 1 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 169 | 0.100 |
Why?
|
| T-Box Domain Proteins | 2 | 2004 | 4 | 0.100 |
Why?
|
| Laparoscopy | 2 | 2011 | 45 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2013 | 24 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2015 | 161 | 0.100 |
Why?
|
| Lymphatic Metastasis | 7 | 2002 | 28 | 0.100 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2003 | 3 | 0.100 |
Why?
|
| Preventive Medicine | 1 | 2013 | 21 | 0.100 |
Why?
|
| Gammapapillomavirus | 2 | 2010 | 4 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2002 | 6 | 0.100 |
Why?
|
| Information Storage and Retrieval | 1 | 2013 | 17 | 0.100 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2012 | 4 | 0.090 |
Why?
|
| Adaptation, Psychological | 2 | 2005 | 76 | 0.090 |
Why?
|
| Syncope | 1 | 2012 | 11 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2014 | 262 | 0.090 |
Why?
|
| Ploidies | 6 | 2007 | 7 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 3 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2012 | 3 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 6 | 0.090 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 6 | 0.090 |
Why?
|
| Motor Activity | 1 | 2014 | 196 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2005 | 186 | 0.090 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 43 | 0.090 |
Why?
|
| Natural Language Processing | 1 | 2013 | 60 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 277 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2011 | 16 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 4 | 2008 | 69 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 97 | 0.080 |
Why?
|
| Infant | 6 | 2019 | 1212 | 0.080 |
Why?
|
| Genes, myc | 2 | 2002 | 3 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 40 | 0.080 |
Why?
|
| Comorbidity | 4 | 2020 | 516 | 0.080 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2020 | 29 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2007 | 8 | 0.080 |
Why?
|
| Child, Preschool | 6 | 2017 | 1430 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2016 | 79 | 0.080 |
Why?
|
| Ureteroscopy | 2 | 2006 | 2 | 0.080 |
Why?
|
| Chi-Square Distribution | 4 | 2013 | 129 | 0.080 |
Why?
|
| Overweight | 1 | 2012 | 262 | 0.080 |
Why?
|
| Minnesota | 5 | 2007 | 51 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2009 | 4 | 0.070 |
Why?
|
| Kidney | 2 | 2006 | 51 | 0.070 |
Why?
|
| Apolipoproteins E | 1 | 2009 | 10 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2009 | 21 | 0.070 |
Why?
|
| Mutation | 3 | 2004 | 86 | 0.070 |
Why?
|
| Curriculum | 1 | 2009 | 51 | 0.070 |
Why?
|
| Vaccines, Conjugate | 2 | 2019 | 59 | 0.070 |
Why?
|
| Heart Failure | 1 | 2014 | 403 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2008 | 1 | 0.070 |
Why?
|
| Opossums | 1 | 2008 | 1 | 0.070 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2008 | 1 | 0.070 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2008 | 1 | 0.070 |
Why?
|
| Sheep | 1 | 2008 | 1 | 0.070 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2008 | 1 | 0.070 |
Why?
|
| Papio | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cricetinae | 1 | 2008 | 2 | 0.070 |
Why?
|
| Haplorhini | 1 | 2008 | 4 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 12 | 0.070 |
Why?
|
| Rats | 1 | 2008 | 33 | 0.070 |
Why?
|
| Chondroma | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hamartoma | 1 | 2007 | 1 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 10 | 0.070 |
Why?
|
| Autopsy | 1 | 2008 | 16 | 0.070 |
Why?
|
| Digital Rectal Examination | 1 | 2007 | 1 | 0.070 |
Why?
|
| Computer-Assisted Instruction | 1 | 2007 | 9 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 14 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2007 | 2 | 0.070 |
Why?
|
| Dextrans | 1 | 2007 | 2 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2008 | 44 | 0.070 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2007 | 4 | 0.070 |
Why?
|
| Bile Duct Neoplasms | 1 | 2007 | 5 | 0.070 |
Why?
|
| Cerebellar Neoplasms | 1 | 2007 | 2 | 0.070 |
Why?
|
| Seminal Vesicles | 1 | 2007 | 1 | 0.070 |
Why?
|
| Medulloblastoma | 1 | 2007 | 3 | 0.070 |
Why?
|
| Stroke | 1 | 2010 | 297 | 0.070 |
Why?
|
| Physicians, Family | 1 | 2007 | 35 | 0.060 |
Why?
|
| Nomograms | 1 | 2007 | 11 | 0.060 |
Why?
|
| Sex Factors | 4 | 2013 | 560 | 0.060 |
Why?
|
| Treatment Failure | 4 | 2014 | 31 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2007 | 43 | 0.060 |
Why?
|
| Orchiectomy | 2 | 2014 | 4 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2004 | 29 | 0.060 |
Why?
|
| Nephrolithiasis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2009 | 235 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Ureteral Obstruction | 1 | 2006 | 1 | 0.060 |
Why?
|
| Primary Health Care | 2 | 2009 | 693 | 0.060 |
Why?
|
| Breast | 2 | 2004 | 66 | 0.060 |
Why?
|
| Ischemia | 1 | 2006 | 4 | 0.060 |
Why?
|
| Oxygen | 1 | 2006 | 14 | 0.060 |
Why?
|
| Socioeconomic Factors | 4 | 2013 | 571 | 0.060 |
Why?
|
| Osteosarcoma | 1 | 2006 | 1 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 10 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2013 | 1233 | 0.060 |
Why?
|
| Immunization Schedule | 2 | 2020 | 127 | 0.060 |
Why?
|
| Dementia | 1 | 2009 | 137 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 410 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2006 | 20 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2006 | 1 | 0.060 |
Why?
|
| Ganglia, Autonomic | 1 | 2006 | 1 | 0.060 |
Why?
|
| Pyridostigmine Bromide | 1 | 2006 | 1 | 0.060 |
Why?
|
| Shy-Drager Syndrome | 1 | 2006 | 1 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 4 | 0.060 |
Why?
|
| Leptin | 1 | 2006 | 24 | 0.060 |
Why?
|
| Kidney Calculi | 1 | 2006 | 6 | 0.060 |
Why?
|
| Body Size | 1 | 2006 | 27 | 0.060 |
Why?
|
| Cystatins | 1 | 2006 | 1 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2006 | 63 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2007 | 60 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 298 | 0.060 |
Why?
|
| Asthma | 2 | 1999 | 375 | 0.060 |
Why?
|
| Radiotherapy Dosage | 2 | 2016 | 3 | 0.060 |
Why?
|
| Health Surveys | 3 | 2014 | 226 | 0.060 |
Why?
|
| Body Image | 1 | 2005 | 20 | 0.060 |
Why?
|
| Diet, Reducing | 1 | 2005 | 22 | 0.060 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2005 | 1 | 0.060 |
Why?
|
| Internationality | 1 | 2005 | 11 | 0.060 |
Why?
|
| Models, Anatomic | 1 | 2005 | 1 | 0.060 |
Why?
|
| Ureteral Neoplasms | 1 | 2005 | 1 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 1 | 0.060 |
Why?
|
| Melphalan | 1 | 2005 | 2 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 2 | 0.050 |
Why?
|
| Amyloidosis | 1 | 2005 | 2 | 0.050 |
Why?
|
| Survivors | 1 | 2006 | 154 | 0.050 |
Why?
|
| Social Behavior | 2 | 2005 | 20 | 0.050 |
Why?
|
| Peripheral Nerves | 1 | 2004 | 2 | 0.050 |
Why?
|
| Penis | 1 | 2004 | 3 | 0.050 |
Why?
|
| Urethral Neoplasms | 1 | 2004 | 1 | 0.050 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 2 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2004 | 5 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 39 | 0.050 |
Why?
|
| Age Distribution | 3 | 2013 | 221 | 0.050 |
Why?
|
| Biomarkers | 3 | 2015 | 284 | 0.050 |
Why?
|
| Pregnancy | 2 | 2021 | 1555 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2005 | 45 | 0.050 |
Why?
|
| Racemases and Epimerases | 1 | 2004 | 1 | 0.050 |
Why?
|
| Nephritis, Interstitial | 1 | 2004 | 3 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2003 | 319 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2017 | 97 | 0.050 |
Why?
|
| Breast Implants | 1 | 2003 | 1 | 0.050 |
Why?
|
| Albumins | 1 | 2003 | 5 | 0.050 |
Why?
|
| Men's Health | 2 | 2014 | 14 | 0.050 |
Why?
|
| Myocardium | 1 | 1983 | 6 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1983 | 5 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2009 | 120 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 203 | 0.050 |
Why?
|
| Albuminuria | 1 | 2003 | 39 | 0.050 |
Why?
|
| Intracranial Aneurysm | 1 | 2003 | 2 | 0.050 |
Why?
|
| Diabetic Nephropathies | 1 | 2003 | 24 | 0.050 |
Why?
|
| Body Constitution | 1 | 2003 | 35 | 0.050 |
Why?
|
| Poisson Distribution | 2 | 2015 | 84 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2003 | 108 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2003 | 64 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2016 | 294 | 0.050 |
Why?
|
| Triglycerides | 1 | 2003 | 78 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 2 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 3 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 13 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 60 | 0.050 |
Why?
|
| Chromogranins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Biopsy | 3 | 2013 | 74 | 0.050 |
Why?
|
| Serotonin | 1 | 2002 | 6 | 0.050 |
Why?
|
| Forecasting | 2 | 2017 | 67 | 0.050 |
Why?
|
| Linear Models | 4 | 2005 | 187 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 445 | 0.050 |
Why?
|
| Genes, BRCA2 | 1 | 2002 | 8 | 0.050 |
Why?
|
| Genes, BRCA1 | 1 | 2002 | 9 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 69 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 70 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2002 | 7 | 0.040 |
Why?
|
| Organizations | 1 | 2021 | 7 | 0.040 |
Why?
|
| Nitrogen Dioxide | 1 | 2021 | 15 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2021 | 36 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2016 | 56 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2021 | 12 | 0.040 |
Why?
|
| Androgen Antagonists | 2 | 1998 | 12 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 120 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2020 | 5 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 44 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 67 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2014 | 12 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2020 | 65 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 41 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 114 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2013 | 164 | 0.040 |
Why?
|
| Aneuploidy | 1 | 1999 | 1 | 0.040 |
Why?
|
| Lipoprotein Lipase | 1 | 1999 | 1 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1999 | 4 | 0.040 |
Why?
|
| Urban Health | 1 | 1999 | 35 | 0.040 |
Why?
|
| Peer Group | 1 | 1999 | 50 | 0.040 |
Why?
|
| Diabetes Complications | 2 | 2011 | 93 | 0.040 |
Why?
|
| Patient Selection | 3 | 2007 | 175 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1999 | 18 | 0.040 |
Why?
|
| Health Education | 1 | 1999 | 79 | 0.040 |
Why?
|
| Community Health Services | 1 | 1999 | 68 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2009 | 261 | 0.040 |
Why?
|
| Educational Status | 2 | 2009 | 163 | 0.040 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1998 | 1 | 0.040 |
Why?
|
| Fontan Procedure | 1 | 1998 | 3 | 0.040 |
Why?
|
| Reoperation | 2 | 2012 | 24 | 0.040 |
Why?
|
| Hypertension | 3 | 2011 | 475 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 311 | 0.030 |
Why?
|
| Genetic Markers | 3 | 2003 | 20 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 1998 | 117 | 0.030 |
Why?
|
| Health Status | 2 | 2010 | 256 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 1997 | 73 | 0.030 |
Why?
|
| Bell Palsy | 1 | 2017 | 14 | 0.030 |
Why?
|
| Palpation | 3 | 2001 | 9 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 1997 | 110 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 1997 | 107 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2008 | 15 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 78 | 0.030 |
Why?
|
| Genotype | 2 | 2009 | 198 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 19 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 112 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 515 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 62 | 0.030 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2015 | 85 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 828 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 28 | 0.030 |
Why?
|
| Survival | 2 | 2006 | 5 | 0.030 |
Why?
|
| Seminoma | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 2014 | 2 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 2014 | 20 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 211 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2009 | 186 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 3 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2015 | 184 | 0.020 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 16 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 84 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2013 | 11 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 23 | 0.020 |
Why?
|
| Causality | 1 | 2013 | 32 | 0.020 |
Why?
|
| Northwestern United States | 1 | 2013 | 53 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 21 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2013 | 33 | 0.020 |
Why?
|
| Graves Disease | 1 | 2012 | 3 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2012 | 6 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2005 | 108 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2012 | 3 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2005 | 21 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2003 | 45 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 43 | 0.020 |
Why?
|
| Urinalysis | 1 | 2011 | 9 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 201 | 0.020 |
Why?
|
| SEER Program | 1 | 2011 | 86 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 130 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 89 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 144 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 41 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 1999 | 6 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 110 | 0.020 |
Why?
|
| Chicago | 2 | 1999 | 24 | 0.020 |
Why?
|
| Papanicolaou Test | 1 | 2009 | 36 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2009 | 47 | 0.020 |
Why?
|
| Manikins | 1 | 2009 | 2 | 0.020 |
Why?
|
| Feedback | 1 | 2009 | 22 | 0.020 |
Why?
|
| Alcoholic Beverages | 1 | 2008 | 13 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2008 | 1 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2008 | 1 | 0.020 |
Why?
|
| Receptors, Somatostatin | 1 | 2008 | 1 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 2 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 18 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 26 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 27 | 0.020 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2007 | 1 | 0.020 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 1 | 0.020 |
Why?
|
| Cognition | 1 | 2009 | 90 | 0.020 |
Why?
|
| Optics and Photonics | 1 | 2007 | 1 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 52 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 88 | 0.020 |
Why?
|
| Injections | 1 | 2007 | 6 | 0.020 |
Why?
|
| Trisomy | 1 | 2007 | 2 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 8 | 0.020 |
Why?
|
| Physical Examination | 1 | 2007 | 20 | 0.020 |
Why?
|
| Immunosuppression | 1 | 2007 | 6 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2007 | 7 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 85 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2007 | 58 | 0.020 |
Why?
|
| Urologic Surgical Procedures | 1 | 2006 | 6 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 1 | 0.020 |
Why?
|
| Rabbits | 1 | 2006 | 5 | 0.020 |
Why?
|
| Random Allocation | 1 | 2006 | 32 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2006 | 44 | 0.020 |
Why?
|
| Ganglia, Sympathetic | 1 | 2006 | 1 | 0.010 |
Why?
|
| Midodrine | 1 | 2006 | 1 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2006 | 1 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 1 | 0.010 |
Why?
|
| Baroreflex | 1 | 2006 | 1 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2006 | 3 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2006 | 2 | 0.010 |
Why?
|
| Arteries | 1 | 2006 | 7 | 0.010 |
Why?
|
| Mathematics | 1 | 2006 | 3 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 6 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 67 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 47 | 0.010 |
Why?
|
| Cystatin C | 1 | 2006 | 14 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2005 | 16 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 29 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 149 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2006 | 138 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 210 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 2005 | 28 | 0.010 |
Why?
|
| Dairy Products | 1 | 2005 | 21 | 0.010 |
Why?
|
| Dietary Fiber | 1 | 2005 | 60 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 5 | 0.010 |
Why?
|
| Energy Intake | 1 | 2005 | 98 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2005 | 25 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 66 | 0.010 |
Why?
|
| Iothalamic Acid | 1 | 2004 | 2 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2005 | 16 | 0.010 |
Why?
|
| Contrast Media | 1 | 2004 | 10 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 94 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 24 | 0.010 |
Why?
|
| Tissue Embedding | 1 | 2004 | 1 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2004 | 3 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 3 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 144 | 0.010 |
Why?
|
| Proteinuria | 1 | 2004 | 24 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 8 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 1983 | 1 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1983 | 1 | 0.010 |
Why?
|
| Mitochondria, Heart | 1 | 1983 | 1 | 0.010 |
Why?
|
| Myelin Sheath | 1 | 1983 | 1 | 0.010 |
Why?
|
| Myofibrils | 1 | 1983 | 1 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 33 | 0.010 |
Why?
|
| TRPP Cation Channels | 1 | 2003 | 1 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2003 | 2 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 8 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 13 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 13 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 27 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 17 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2003 | 1 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2003 | 8 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 2003 | 7 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2003 | 3 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2003 | 12 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 59 | 0.010 |
Why?
|
| Chromogranin A | 1 | 2002 | 1 | 0.010 |
Why?
|
| Epithelium | 1 | 2002 | 2 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 2002 | 2 | 0.010 |
Why?
|
| Allelic Imbalance | 1 | 2002 | 1 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2003 | 42 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2002 | 2 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 382 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 32 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2001 | 15 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2001 | 53 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2000 | 4 | 0.010 |
Why?
|
| Cats | 1 | 1999 | 7 | 0.010 |
Why?
|
| Centromere | 1 | 1999 | 1 | 0.010 |
Why?
|
| Uncompensated Care | 1 | 1999 | 5 | 0.010 |
Why?
|
| Allergens | 1 | 1999 | 7 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1 | 0.010 |
Why?
|
| Air Pollution, Indoor | 1 | 1999 | 7 | 0.010 |
Why?
|
| DNA Probes | 1 | 1999 | 2 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 4 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 1999 | 2 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 1999 | 13 | 0.010 |
Why?
|
| Pelvis | 1 | 1998 | 2 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 19 | 0.010 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 1998 | 1 | 0.010 |
Why?
|
| Tricuspid Atresia | 1 | 1998 | 1 | 0.010 |
Why?
|
| Heart Atria | 1 | 1998 | 2 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1998 | 2 | 0.010 |
Why?
|
| School Health Services | 1 | 1998 | 39 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1998 | 54 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1998 | 17 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1999 | 352 | 0.010 |
Why?
|
| Family | 1 | 1997 | 99 | 0.010 |
Why?
|